Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
(Brixham Report BL/B/2373)
Retatrutide (LY3437943) is an investigational medicinal product (IMP) a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under clinical evaluation for obesity and metabolic disease
Effect of GLP-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: systematic review and meta-analysis
Figure 2 3.2.1 Atrial fibrillation The eight studies collected for mate-analysis of the effect of GLP-1RA on atrial fibrillation are listed in Figure 3
US$ 29.39
US$ 28.11
US$ 26.42
US$ 23.90
US$ 21.14
US$ 20.71
